AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid ...

PRESS RELEASEAB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE ...

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Syndax Pharmaceuticals (Nasdaq: SNDX) and the World Orphan Drug Alliance (WODA) today announced a collaboration to expand access to the Company’s first-in-class menin inhibitor, Revuforj ® (revumenib) ...
Fierce Pharma

Verastem nixes KRAS G12C plans in non-small cell lung cancer

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...

ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy

ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time ...

Pancreatic cancer is among the deadliest cancers. A new drug being tested at Penn is giving patients and doctors hope.

The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer ...
Oncology Nurse Advisor

Combination of Asciminib Plus a TKI Offers Hope of Treatment-Free Remission in CML

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.
Le Lézard

GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...
The Royal Gazette

Baby girl born four months early thriving after 15 years

Julene Darrell was born so premature in 2010 that every day she lived was a miracle. She arrived in the world at about 25 ...

BioMendics Brings New Hope for Epidermolysis Bullosa Simplex Patients as TAMES--02 Trial Advances and JPM Week Approaches

As BioMendics prepares to share its progress during the 2026 J.P. Morgan Healthcare Conference and Biotech Showcase, the Ohio-based biotech is advancing what could become the first disease-modifying ...
Le Lézard

Castration-sensitive Prostate Cancer Market Projected to Grow at a 13.2% CAGR (2020-2034), Driven by Expanded Approval and Wider Commercialization Opportunity in nmCSPC Segment ...

DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual ...